Medicare Program; Virtual Meeting of the Medicare Evidence Development and Coverage Advisory Committee-December 7, 2022, 61331-61333 [2022-22067]
Download as PDF
61331
Federal Register / Vol. 87, No. 195 / Tuesday, October 11, 2022 / Notices
elements of these messages will include
the unique public health laboratory
specimen ID and a summary of
specimen testing results to date.
Sites participating in detection and
characterization of AR Neisseria
gonorrhoeae, including antimicrobial
susceptibility testing of Neisseria
gonorrhoeae will provide the following
to the STD Laboratory Reference and
Research Branch (SLRRB) at CDC—
Division of STD Prevention (DSTDP):
1. Annually, participating laboratories
will provide an Evaluation and
Performance Measure Report. Data will
be used to indicate progress made
toward program objectives and
challenges encountered.
2. Participating laboratories will
notify CDC DTSDP of any isolate(s)
identified to demonstrate an ‘‘alert’’ MIC
as defined by SLRRB within one
working day. Laboratories will utilize
REDCap to communicate these findings.
The elements of these messages will
include the unique public health
laboratory specimen ID and a summary
of specimen testing results to date.
3. Participating laboratories will
report all testing results to CDC,
requested at least monthly, by email,
REDCap, or HL7 using an online webportal transmission. This information
will be used to: (a) identify and track
antibiotic resistant pathogens and
emerging patterns of resistance; and (b)
aid public health departments and
healthcare facilities in timely
responding to antibiotic resistant public
health threats and outbreaks.
Participating laboratories will utilize
secure public health messaging
protocols to transfer results data to CDC,
submitting facilities and clinical
laboratories. For messaging to CDC,
these messaging protocols will be based
in REDCap or the AIMS platform. The
REDCap and AIMS platforms are secure
environments that provide shared
services to assist public health
laboratories in the transport, validation,
and routing of electronic data. AIMS is
transitioning to the use of HL7
messaging for data to be transmitted in
real-time, allowing more frequent
reporting of results while
simultaneously lessening burden on
public health laboratories.
CDC requests OMB approval for an
estimated 4,705 annualized burden
hours. There is no cost to respondents
other than their time to participate.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Type of respondents
Form name
Public Health Laboratories ................
Annual Report of Bacterial Specimen Testing Methods.
Annual Evaluation and Performance
Measurement Report for Bacterial
Specimen Testing.
Monthly Testing Results Reports—
Bacterial Specimen Testing.
AR Lab Network Alerts—Bacterial
Specimen Testing.
Annual Evaluation and Performance
Measurement Report (Candida
identification).
Monthly Testing Results Reports—
Candida identification.
AR Lab Network Alerts—Candida
auris.
Annual Evaluation and Performance
Measurement Report (Neisseria
gonorrhoeae).
Monthly Testing Results Reports—
Neisseria gonorrhoeae.
AR Lab Network Alerts—Neisseria
gonorrhoeae.
Public Health Laboratories ................
Public Health Laboratories ................
Public Health Laboratories ................
Public Health Laboratories ................
Public Health Laboratories ................
Public Health Laboratories ................
Public Health Laboratories ................
Public Health Laboratories ................
Public Health Laboratories ................
Total ...........................................
...........................................................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2022–22027 Filed 10–7–22; 8:45 am]
6/60
6
56
1
4
224
56
12
4
2688
56
34
6/60
190
Up to 56
1
2
112
Up to 56
12
2
1344
Up to 56
13
6/60
73
Up to 56
1
1
56
Up to 56
1
6/60
6
Up to 56
1
6/60
6
........................
........................
........................
4705
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
khammond on DSKJM1Z7X2PROD with NOTICES
Medicare Program; Virtual Meeting of
the Medicare Evidence Development
and Coverage Advisory Committee—
December 7, 2022
Centers for Medicare &
Medicaid Services (CMS), Health and
Human Services (HHS).
AGENCY:
Jkt 259001
PO 00000
Frm 00056
Fmt 4703
Total burden
(in hours)
1
[CMS–3431–N]
17:37 Oct 07, 2022
Average
burden per
response
(in hours)
56
BILLING CODE 4163–18–P
VerDate Sep<11>2014
Number of
responses per
respondent
Sfmt 4703
ACTION:
Notice.
This notice announces a
virtual public meeting of the Medicare
Evidence Development & Coverage
Advisory Committee (MEDCAC)
(‘‘Committee’’) will be held on
Wednesday, December 7, 2022. National
Coverage Determinations resulting in
coverage with evidence development
(CED) can expedite earlier Medicare
beneficiary access to innovative
technology while ensuring that
systematic patient safeguards are in
place to reduce the risks inherent to
new technologies, or to new
SUMMARY:
E:\FR\FM\11OCN1.SGM
11OCN1
khammond on DSKJM1Z7X2PROD with NOTICES
61332
Federal Register / Vol. 87, No. 195 / Tuesday, October 11, 2022 / Notices
applications of older technologies. This
meeting will examine the general
requirements for clinical studies
submitted for CMS coverage requiring
CED. The MEDCAC will evaluate the
CED criteria to assure that CED studies
are evaluated with consistent, feasible,
transparent and methodologically
rigorous criteria and advise CMS on
whether the criteria are appropriate to
ensure that CED-approved studies will
produce reliable evidence that CMS can
rely on to help determine whether a
particular item or service is reasonable
and necessary. This meeting is open to
the public in accordance with the
Federal Advisory Committee Act.
DATES:
Meeting Date: The virtual meeting
will be held on Wednesday, December
7, 2022 from 10:00 a.m. until 5:00 p.m.,
Eastern Standard Time (EST).
Deadline for Submission of Written
Comments: Written comments must be
received at the email address specified
in the ADDRESSES section of this notice
by 5:00 p.m., Eastern Standard Time
(EST), on Monday, November 7, 2022.
Once submitted, all comments are final.
Deadlines for Speaker Registration
and Presentation Materials: The
deadline to register to be a speaker and
to submit PowerPoint presentation
materials and writings that will be used
in support of an oral presentation is 5:00
p.m., EST, on Monday, November 7,
2022. Speakers may register by phone or
via email by contacting the person listed
in the FOR FURTHER INFORMATION
CONTACT section of this notice.
Presentation materials must be received
at the email address specified in the
ADDRESSES section of this notice.
Submission of Presentations and
Comments: Presentation materials and
written comments that will be presented
at the meeting must be submitted via
email to MedCACpresentations@
cms.hhs.gov section of this notice by
Monday November 7, 2022.
Deadline for All Other Attendees
Registration: Individuals who want to
join the meeting may register online at
https://cms.zoomgov.com/webinar/
register/WN_
CsJL7k7kQcyY0Z20OR6eqw by 11:59
p.m. EST, on Tuesday, December 6,
2022.
Webinar and Teleconference Meeting
Information: Teleconference dial-in
instructions, and related webinar details
will be posted on the meeting agenda,
which will be available on the CMS
website https://www.cms.gov/medicarecoverage-database/indexes/medcacmeetings-index.aspx?bc=
BAAAAAAAAAAA&. Participants in
the MEDCAC meeting will require the
VerDate Sep<11>2014
17:37 Oct 07, 2022
Jkt 259001
following: A computer, laptop or
smartphone where the Zoom
application needs to be downloaded; a
strong Wi-Fi or an internet connection
and access to use Chrome or Firefox
web browser and a webcam if the
meeting participant is scheduled to
speak or make a presentation during the
meeting.
Deadline for Submitting a Request for
Special Accommodations: Individuals
viewing or listening to the meeting who
are hearing or visually impaired and
have special requirements, or a
condition that requires special
assistance, should send an email to the
MEDCAC Coordinator as specified in
the FOR FURTHER INFORMATION CONTACT
section of this notice no later than 5:00
p.m., EST on Monday, November 14,
2022.
ADDRESSES: Due to the current COVID–
19 public health emergency, the Panel
meeting will be held virtually and will
not occur at the campus of the Centers
for Medicare & Medicaid Services
(CMS), Central Building, 7500 Security
Boulevard, Baltimore, Maryland 21244.
FOR FURTHER INFORMATION CONTACT: Tara
Hall, MEDCAC Coordinator, via email at
Tara.Hall@cms.hhs.gov or by phone
410–786–4347.
SUPPLEMENTARY INFORMATION:
I. Background
MEDCAC, formerly known as the
Medicare Coverage Advisory Committee
(MCAC), is advisory in nature, with all
final coverage decisions resting with
CMS. MEDCAC is used to supplement
CMS’ internal expertise. Accordingly,
the advice rendered by the MEDCAC is
most useful when it results from a
process of full scientific inquiry and
thoughtful discussion, in an open
forum, with careful framing of
recommendations and clear
identification of the basis of those
recommendations. MEDCAC members
are valued for their background,
education, and expertise in a wide
variety of scientific, clinical, and other
related fields. (For more information on
MEDCAC, see the MEDCAC Charter
(https://www.cms.gov/Regulations-andGuidance/Guidance/FACA/Downloads/
medcaccharter.pdf) and the CMS
Guidance Document, Factors CMS
Considers in Referring Topics to the
MEDCAC (https://www.cms.gov/
medicare-coverage-database/details/
medicare-coverage-documentdetails.aspx?MCDId=10).
II. Meeting Topic and Format
This notice announces the
Wednesday, December 7, 2022, virtual
public meeting of the Committee. This
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
meeting will examine the requirements
for clinical studies submitted for CMS
coverage under CED. It has been nearly
8 years since the criteria for CED were
last evaluated and codified. In that time,
not only have technologies become
more complex, but there has been
growing appreciation and commitment
to transparency in decision-making, to
making certain that study
methodologies are ‘‘fit to purpose’’ as
determined by the topic, questions
asked, health outcomes studied, and to
making certain that the populations
studied are representative of the
diversity in the Medicare beneficiary
population. For example, some
questions may be sufficiently answered
through analysis of real-world evidence
including data from clinical registries,
electronic health records, and
administrative claims. Any decision
about whether an item or service is
reasonable and necessary must,
minimally, be sensitive to these
commitments as well as to ensuring that
study participants’ interests are
respected and protected. The MEDCAC
will evaluate the CED criteria to assure
that CED studies are evaluated with
consistent, feasible, transparent and
methodologically rigorous criteria and
advise CMS on whether the criteria are
appropriate to ensure that CEDapproved studies will produce reliable
evidence that CMS can rely on to help
determine whether a particular item or
service is reasonable and necessary.
Background information about this
topic, including panel materials, is
available at https://www.cms.gov/
medicare-coverage-database/indexes/
medcac-meetings-index.aspx?bc=
BAAAAAAAAAAA&. Electronic copies
of all the meeting materials will be on
the CMS website no later than 2
business days before the meeting. We
encourage the participation of
organizations, researchers and people
with expertise or interest in the
thoughtful, efficient design and
implementation of clinical studies
whose goals are to improve the health
of people, especially Medicare
beneficiaries. This meeting is open to
the public. The Committee will hear
oral presentations from the public for
approximately 45 minutes. Time
allotted for each presentation may be
limited. If the number of registrants
requesting to speak is greater than what
can be reasonably accommodated
during the scheduled open public
hearing session, we may conduct a
lottery to determine the speakers for the
scheduled open public hearing session.
The contact person will notify
interested persons regarding their
E:\FR\FM\11OCN1.SGM
11OCN1
Federal Register / Vol. 87, No. 195 / Tuesday, October 11, 2022 / Notices
request to speak no later than 1 week
from the speaker registration deadline
specified in the DATES section of this
notice. Your comments must focus on
issues specific to the list of topics that
we have proposed to the Committee.
The list of research topics to be
discussed at the meeting will be
available on the following website prior
to the meeting https://www.cms.gov/
medicare-coverage-database/indexes/
medcac-meetings-index.aspx?bc=
BAAAAAAAAAAA&. We require that
you declare at the meeting whether you
have any financial involvement with
manufacturers (or their competitors) of
any items or services being discussed.
Speakers presenting at the MEDCAC
meeting must include a full disclosure
slide as their second slide in their
presentation for financial interests (for
example, type of financial association—
consultant, research support, advisory
board, and an indication of level, such
as minor association <$10,000 or major
association >$10,000) as well as
intellectual conflicts of interest (for
example, involvement in a federal or
nonfederal advisory committee that has
discussed the issue) that may pertain in
any way to the subject of this meeting.
If you are representing an organization,
we require that you also disclose
conflict of interest information for that
organization. If you do not have a
PowerPoint presentation, you will need
to present the full disclosure
information requested previously at the
beginning of your statement to the
Committee.
The Committee will deliberate openly
on the topics under consideration.
Interested persons may observe the
deliberations, but the Committee will
not hear further comments during this
time except at the request of the
chairperson. The Committee will also
allow a 15-minute unscheduled open
public session for any attendee to
address issues specific to the topics
under consideration. At the conclusion
of the day, the members will vote and
the Committee will make its
recommendation(s) to CMS.
khammond on DSKJM1Z7X2PROD with NOTICES
III. Registration Instructions
CMS’ Coverage and Analysis Group is
coordinating meeting registration. While
there is no registration fee, individuals
must register to attend. You may register
online at https://cms.zoomgov.com/
webinar/register/WN_
CsJL7k7kQcyY0Z20OR6eqw or by phone
by contacting the person listed in the
FOR FURTHER INFORMATION CONTACT
section of this notice by the deadline
listed in the DATES section of this notice.
VerDate Sep<11>2014
17:37 Oct 07, 2022
Jkt 259001
Please provide your full name (as it
appears on your state-issued driver’s
license), address, organization,
telephone number(s), and email address.
You will receive a registration
confirmation with instructions for your
participation at the virtual public
meeting.
61333
October 11, 2022, is extended to
November 16, 2022.
The comment period for the
information collection request
published in the August 9, 2022 Federal
Register (87 FR 48482) is extended to
November 16, 2022.
DATES:
When commenting, please
reference the document identifier or
OMB control number. To be assured
consideration, comments and
recommendations must be submitted in
any one of the following ways:
ADDRESSES:
IV. Collection of Information
This document does not impose
information collection requirements,
that is, reporting, recordkeeping or
third-party disclosure requirements.
Consequently, there is no need for
review by the Office of Management and
Budget under the authority of the
Paperwork Reduction Act of 1995 (44
U.S.C. Chapter 35).
The Chief Medical Officer and
Director of the Center for Clinical
Standards and Quality for the Centers
for Medicare & Medicaid Services
(CMS), Lee A. Fleisher, having reviewed
and approved this document, authorizes
Lynette Wilson, who is the Federal
Register Liaison, to electronically sign
this document for purposes of
publication in the Federal Register.
Dated: October 5, 2022.
Lynette Wilson,
Federal Register Liaison, Centers for Medicare
& Medicaid Services.
[FR Doc. 2022–22067 Filed 10–7–22; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
1. Electronically. You may send your
comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) that are accepting
comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: Document Identifier/OMB
Control Number ll, Room C4–26–05,
7500 Security Boulevard, Baltimore,
Maryland 21244–1850.
To obtain copies of a supporting
statement and any related forms for the
proposed collection(s) summarized in
this notice, please access the CMS PRA
website by copying and pasting the
following web address into your web
browser: https://www.cms.gov/
Regulations-and-Guidance/Legislation/
PaperworkReductionActof1995/PRAListing.
[Document Identifier: CMS–437A and CMS–
437B]
FOR FURTHER INFORMATION CONTACT:
Agency Information Collection
Activities: Proposed Collection;
Extension of Comment Period
SUPPLEMENTARY INFORMATION:
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Agency information collection
activities: Proposed collection; comment
request; extension of comment period.
AGENCY:
This notice extends the
comment period for a 60-day notice
request for proposed information
collection request associated with the
notice [Document Identifier: CMS–437A
and CMS–437B] entitled ‘‘Rehabilitation
Unit and Hospital Criteria Worksheet’’
that was published in the August 9,
2022 Federal Register. The comment
period for the information collection
request, which would have ended on
SUMMARY:
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
William N. Parham at (410) 786–4669.
In the FR
Doc. 2022–17063 of August 9, 2022 (87
FR 48482), we published a Paperwork
Reduction Act notice requesting a 60day public comment period for the
document entitled ‘‘Rehabilitation Unit
and Hospital Criteria Worksheet.’’ There
were technical delays associated with
making the information collection
request publicly available; therefore, in
this notice we are extending the
comment period from the date originally
listed in the August 9, 2022, notice.
Dated: October 5, 2022.
William N. Parham, III,
Director, Paperwork Reduction Staff, Office
of Strategic Operations and Regulatory
Affairs.
[FR Doc. 2022–22066 Filed 10–7–22; 8:45 am]
BILLING CODE 4120–01–P
E:\FR\FM\11OCN1.SGM
11OCN1
Agencies
[Federal Register Volume 87, Number 195 (Tuesday, October 11, 2022)]
[Notices]
[Pages 61331-61333]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-22067]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[CMS-3431-N]
Medicare Program; Virtual Meeting of the Medicare Evidence
Development and Coverage Advisory Committee--December 7, 2022
AGENCY: Centers for Medicare & Medicaid Services (CMS), Health and
Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces a virtual public meeting of the Medicare
Evidence Development & Coverage Advisory Committee (MEDCAC)
(``Committee'') will be held on Wednesday, December 7, 2022. National
Coverage Determinations resulting in coverage with evidence development
(CED) can expedite earlier Medicare beneficiary access to innovative
technology while ensuring that systematic patient safeguards are in
place to reduce the risks inherent to new technologies, or to new
[[Page 61332]]
applications of older technologies. This meeting will examine the
general requirements for clinical studies submitted for CMS coverage
requiring CED. The MEDCAC will evaluate the CED criteria to assure that
CED studies are evaluated with consistent, feasible, transparent and
methodologically rigorous criteria and advise CMS on whether the
criteria are appropriate to ensure that CED-approved studies will
produce reliable evidence that CMS can rely on to help determine
whether a particular item or service is reasonable and necessary. This
meeting is open to the public in accordance with the Federal Advisory
Committee Act.
DATES:
Meeting Date: The virtual meeting will be held on Wednesday,
December 7, 2022 from 10:00 a.m. until 5:00 p.m., Eastern Standard Time
(EST).
Deadline for Submission of Written Comments: Written comments must
be received at the email address specified in the ADDRESSES section of
this notice by 5:00 p.m., Eastern Standard Time (EST), on Monday,
November 7, 2022. Once submitted, all comments are final.
Deadlines for Speaker Registration and Presentation Materials: The
deadline to register to be a speaker and to submit PowerPoint
presentation materials and writings that will be used in support of an
oral presentation is 5:00 p.m., EST, on Monday, November 7, 2022.
Speakers may register by phone or via email by contacting the person
listed in the FOR FURTHER INFORMATION CONTACT section of this notice.
Presentation materials must be received at the email address specified
in the ADDRESSES section of this notice.
Submission of Presentations and Comments: Presentation materials
and written comments that will be presented at the meeting must be
submitted via email to [email protected] section of this
notice by Monday November 7, 2022.
Deadline for All Other Attendees Registration: Individuals who want
to join the meeting may register online at https://cms.zoomgov.com/webinar/register/WN_CsJL7k7kQcyY0Z20OR6eqw by 11:59 p.m. EST, on
Tuesday, December 6, 2022.
Webinar and Teleconference Meeting Information: Teleconference
dial-in instructions, and related webinar details will be posted on the
meeting agenda, which will be available on the CMS website https://www.cms.gov/medicare-coverage-database/indexes/medcac-meetings-index.aspx?bc=BAAAAAAAAAAA&. Participants in the MEDCAC meeting will
require the following: A computer, laptop or smartphone where the Zoom
application needs to be downloaded; a strong Wi-Fi or an internet
connection and access to use Chrome or Firefox web browser and a webcam
if the meeting participant is scheduled to speak or make a presentation
during the meeting.
Deadline for Submitting a Request for Special Accommodations:
Individuals viewing or listening to the meeting who are hearing or
visually impaired and have special requirements, or a condition that
requires special assistance, should send an email to the MEDCAC
Coordinator as specified in the FOR FURTHER INFORMATION CONTACT section
of this notice no later than 5:00 p.m., EST on Monday, November 14,
2022.
ADDRESSES: Due to the current COVID-19 public health emergency, the
Panel meeting will be held virtually and will not occur at the campus
of the Centers for Medicare & Medicaid Services (CMS), Central
Building, 7500 Security Boulevard, Baltimore, Maryland 21244.
FOR FURTHER INFORMATION CONTACT: Tara Hall, MEDCAC Coordinator, via
email at [email protected] or by phone 410-786-4347.
SUPPLEMENTARY INFORMATION:
I. Background
MEDCAC, formerly known as the Medicare Coverage Advisory Committee
(MCAC), is advisory in nature, with all final coverage decisions
resting with CMS. MEDCAC is used to supplement CMS' internal expertise.
Accordingly, the advice rendered by the MEDCAC is most useful when it
results from a process of full scientific inquiry and thoughtful
discussion, in an open forum, with careful framing of recommendations
and clear identification of the basis of those recommendations. MEDCAC
members are valued for their background, education, and expertise in a
wide variety of scientific, clinical, and other related fields. (For
more information on MEDCAC, see the MEDCAC Charter (https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/Downloads/medcaccharter.pdf) and
the CMS Guidance Document, Factors CMS Considers in Referring Topics to
the MEDCAC (https://www.cms.gov/medicare-coverage-database/details/medicare-coverage-document-details.aspx?MCDId=10).
II. Meeting Topic and Format
This notice announces the Wednesday, December 7, 2022, virtual
public meeting of the Committee. This meeting will examine the
requirements for clinical studies submitted for CMS coverage under CED.
It has been nearly 8 years since the criteria for CED were last
evaluated and codified. In that time, not only have technologies become
more complex, but there has been growing appreciation and commitment to
transparency in decision-making, to making certain that study
methodologies are ``fit to purpose'' as determined by the topic,
questions asked, health outcomes studied, and to making certain that
the populations studied are representative of the diversity in the
Medicare beneficiary population. For example, some questions may be
sufficiently answered through analysis of real-world evidence including
data from clinical registries, electronic health records, and
administrative claims. Any decision about whether an item or service is
reasonable and necessary must, minimally, be sensitive to these
commitments as well as to ensuring that study participants' interests
are respected and protected. The MEDCAC will evaluate the CED criteria
to assure that CED studies are evaluated with consistent, feasible,
transparent and methodologically rigorous criteria and advise CMS on
whether the criteria are appropriate to ensure that CED-approved
studies will produce reliable evidence that CMS can rely on to help
determine whether a particular item or service is reasonable and
necessary.
Background information about this topic, including panel materials,
is available at https://www.cms.gov/medicare-coverage-database/indexes/medcac-meetings-index.aspx?bc=BAAAAAAAAAAA&. Electronic copies of all
the meeting materials will be on the CMS website no later than 2
business days before the meeting. We encourage the participation of
organizations, researchers and people with expertise or interest in the
thoughtful, efficient design and implementation of clinical studies
whose goals are to improve the health of people, especially Medicare
beneficiaries. This meeting is open to the public. The Committee will
hear oral presentations from the public for approximately 45 minutes.
Time allotted for each presentation may be limited. If the number of
registrants requesting to speak is greater than what can be reasonably
accommodated during the scheduled open public hearing session, we may
conduct a lottery to determine the speakers for the scheduled open
public hearing session. The contact person will notify interested
persons regarding their
[[Page 61333]]
request to speak no later than 1 week from the speaker registration
deadline specified in the DATES section of this notice. Your comments
must focus on issues specific to the list of topics that we have
proposed to the Committee. The list of research topics to be discussed
at the meeting will be available on the following website prior to the
meeting https://www.cms.gov/medicare-coverage-database/indexes/medcac-meetings-index.aspx?bc=BAAAAAAAAAAA&. We require that you declare at
the meeting whether you have any financial involvement with
manufacturers (or their competitors) of any items or services being
discussed. Speakers presenting at the MEDCAC meeting must include a
full disclosure slide as their second slide in their presentation for
financial interests (for example, type of financial association--
consultant, research support, advisory board, and an indication of
level, such as minor association <$10,000 or major association
>$10,000) as well as intellectual conflicts of interest (for example,
involvement in a federal or nonfederal advisory committee that has
discussed the issue) that may pertain in any way to the subject of this
meeting. If you are representing an organization, we require that you
also disclose conflict of interest information for that organization.
If you do not have a PowerPoint presentation, you will need to present
the full disclosure information requested previously at the beginning
of your statement to the Committee.
The Committee will deliberate openly on the topics under
consideration. Interested persons may observe the deliberations, but
the Committee will not hear further comments during this time except at
the request of the chairperson. The Committee will also allow a 15-
minute unscheduled open public session for any attendee to address
issues specific to the topics under consideration. At the conclusion of
the day, the members will vote and the Committee will make its
recommendation(s) to CMS.
III. Registration Instructions
CMS' Coverage and Analysis Group is coordinating meeting
registration. While there is no registration fee, individuals must
register to attend. You may register online at https://cms.zoomgov.com/webinar/register/WN_CsJL7k7kQcyY0Z20OR6eqw or by phone by contacting
the person listed in the FOR FURTHER INFORMATION CONTACT section of
this notice by the deadline listed in the DATES section of this notice.
Please provide your full name (as it appears on your state-issued
driver's license), address, organization, telephone number(s), and
email address. You will receive a registration confirmation with
instructions for your participation at the virtual public meeting.
IV. Collection of Information
This document does not impose information collection requirements,
that is, reporting, recordkeeping or third-party disclosure
requirements. Consequently, there is no need for review by the Office
of Management and Budget under the authority of the Paperwork Reduction
Act of 1995 (44 U.S.C. Chapter 35).
The Chief Medical Officer and Director of the Center for Clinical
Standards and Quality for the Centers for Medicare & Medicaid Services
(CMS), Lee A. Fleisher, having reviewed and approved this document,
authorizes Lynette Wilson, who is the Federal Register Liaison, to
electronically sign this document for purposes of publication in the
Federal Register.
Dated: October 5, 2022.
Lynette Wilson,
Federal Register Liaison, Centers for Medicare & Medicaid Services.
[FR Doc. 2022-22067 Filed 10-7-22; 8:45 am]
BILLING CODE 4120-01-P